In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry - Fragment-Based Drug Discovery - page 173

Figure 7.10 A commercial FTMS systemwith a front-end nanoflow LC system. The schematic
cutaway view depicts the sequential vacuum stages that are required to transfer ions in the ESI
source (formed at atmospheric pressure) to the mass analyzer cell of the FTMS (10 −10 mbar).
7.10 Mass Spectrometry and In Situ DCC
In the early days of DCC, the integration of synthesis with screening was touted as a key
advantage of this approach. What actually emerged as the standard in situ DCL screen-
ing approach has, probably owing to analytical constraints, deviated somewhat from this
original conception and instead an indirect method that screens for ligand enrichment has
evolved. This indirect screening approach carries out the analysis of identical DCLs twice,